Economic Analysis of Finasteride: A Model-Based Approach Using Data from the Proscar Long-Term Efficacy and Safety Study
June 1999
in “
Clinical Therapeutics
”
TLDR Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.
A study using data from the Proscar long-term efficacy and safety study found that finasteride is a cost-effective treatment for benign prostatic hyperplasia (BPH) compared to watchful waiting and terazosin over a 2-year period. Finasteride reduces the risk of acute urinary retention and surgery, resulting in cost savings. The study recommends finasteride as a viable option for BPH treatment.